2022
DOI: 10.1080/13696998.2021.2020569
|View full text |Cite
|
Sign up to set email alerts
|

Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
2
1
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 54 publications
0
2
1
1
Order By: Relevance
“…Thus, if the TAVR device cost is lowered to 26,794 USD, TAVR would be highly costeffective. Some studies have reported that TAVR is cost-effective in their countries (16)(17)(18)(19). However, in the present study, we concluded that TAVR is not currently cost-effective in China due to several reasons.…”
Section: Discussioncontrasting
confidence: 66%
“…Thus, if the TAVR device cost is lowered to 26,794 USD, TAVR would be highly costeffective. Some studies have reported that TAVR is cost-effective in their countries (16)(17)(18)(19). However, in the present study, we concluded that TAVR is not currently cost-effective in China due to several reasons.…”
Section: Discussioncontrasting
confidence: 66%
“…However, the study reported the 5-year cost only, and it was not limited to patients with low EF. 25…”
Section: Discussionmentioning
confidence: 99%
“…However, the study reported the 5-year cost only, and it was not limited to patients with low EF. 25 The major limitations of the study are the retrospective design and the lack of randomization. Patients were assigned to each group based on their characteristics, which led to significant variations in the baseline characteristics.…”
Section: Discussionmentioning
confidence: 99%
“…3 Una gran proporción de pacientes seleccionados para cirugía de la válvula aórtica se someten a un reemplazo con una prótesis biológica de la válvula cardiaca; 2,3 sin embargo, el costo de esta opción terapéutica, ahora aceptada en todo el mundo, es alto no solo en términos de gastos hospitalarios, sino también debido al costo de la válvula cardiaca protésica. 4,5 La válvula cardiaca (VC) bioprotésica INC (Instituto Nacional de Cardiología "Ignacio Chávez"), desarrollada siguiendo la normativa internacional, es una alternativa a las prótesis biológicas quirúrgicas o transcatéter comerciales, las cuales son altamente costosas para el sistema mexicano de salud pública.…”
Section: Introductionunclassified